Medical-grade monophasic filler with 20mg/mL cross-linked HA, featuring patented BDDE residue removal technology (＜0.1ppm). Certified 12-18 month duration with 92% viscoelasticity retention. Ideal for structural augmentation in deep tissue layers (dermis-subcutaneous junction).

Cross-Linking Technology:
• Patented BDDE purification process
• Uniform 3D matrix structure
• 0.22μm terminal filtration

◉ Professional Kit Includes:
• 1×1mL sterile syringe
• 2×27G ½” needles
• Lot-controlled packaging
• 2-25°C storage

Clinical Protocol:
1. Aseptic site preparation
2. 25G+ cannula recommended
3. Retrograde linear threading
4. Post-injection molding
✦ Avoid perioral zones

Medical Notice: Results may vary ±20% based on injection technique and tissue characteristics. BR Pharm certificate: KFDA 2023-HA-028. Not for vascular compartments. Contains trace HA derivatives (≤0.01%).